277 related articles for article (PubMed ID: 8420542)
1. Hypercalcemia of malignancy: pathophysiology and implications for treatment.
Theriault RL
Oncology (Williston Park); 1993 Jan; 7(1):47-50; discussion 52-5. PubMed ID: 8420542
[TBL] [Abstract][Full Text] [Related]
2. Pathophysiology and management of severe hypercalcemia.
Nussbaum SR
Endocrinol Metab Clin North Am; 1993 Jun; 22(2):343-62. PubMed ID: 8325291
[TBL] [Abstract][Full Text] [Related]
3. Management of hypercalcemia in breast cancer.
Theriault RL
Oncology (Williston Park); 1990 Feb; 4(2):43-6; discussion 50. PubMed ID: 2143669
[TBL] [Abstract][Full Text] [Related]
4. Hypercalcemia and bone resorption in malignancy.
Walls J; Bundred N; Howell A
Clin Orthop Relat Res; 1995 Mar; (312):51-63. PubMed ID: 7634618
[TBL] [Abstract][Full Text] [Related]
5. Hypercalcemia of malignancy in the palliative care patient: a treatment strategy.
Kovacs CS; MacDonald SM; Chik CL; Bruera E
J Pain Symptom Manage; 1995 Apr; 10(3):224-32. PubMed ID: 7543127
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms and treatment of hypercalcemia of malignancy.
Clines GA
Curr Opin Endocrinol Diabetes Obes; 2011 Dec; 18(6):339-46. PubMed ID: 21897221
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
Kanakis I; Kousidou OCh; Karamanos NK
In Vivo; 2005; 19(1):311-8. PubMed ID: 15796191
[TBL] [Abstract][Full Text] [Related]
8. [Biphosphonates in oncology].
Khosravi Shahi P; Díaz Muñoz de la Espada V
An Med Interna; 2005 Nov; 22(11):544-7. PubMed ID: 16454591
[TBL] [Abstract][Full Text] [Related]
9. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
McMahan J; Linneman T
Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms and treatment for bone metastases.
Clines GA; Guise TA
Clin Adv Hematol Oncol; 2004 May; 2(5):295-302. PubMed ID: 16163196
[TBL] [Abstract][Full Text] [Related]
11. Cancer-induced hypercalcemia.
Lumachi F; Brunello A; Roma A; Basso U
Anticancer Res; 2009 May; 29(5):1551-5. PubMed ID: 19443365
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
Rosen LS
Semin Oncol; 2002 Dec; 29(6 Suppl 21):28-32. PubMed ID: 12584692
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
14. [Current use of bisphosphonates in clinical oncology].
Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates: clinical experience.
Coleman RE
Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
[TBL] [Abstract][Full Text] [Related]
16. [Hypercalcemia in malignant diseases. Physiopathology and treatment].
Aasarød K; Lamvik J
Tidsskr Nor Laegeforen; 1989 Apr; 109(12):1293-6. PubMed ID: 2734758
[TBL] [Abstract][Full Text] [Related]
17. Treating cancer-related hypercalcemia with gallium nitrate.
Leyland-Jones B
J Support Oncol; 2004; 2(6):509-16. PubMed ID: 15605917
[TBL] [Abstract][Full Text] [Related]
18. [Refractory hypercalcemia in patient with lung cancer].
Grzywacz A; Dziuk M; Niemczyk S
Pol Merkur Lekarski; 2014 Apr; 36(214):261-4. PubMed ID: 24868900
[TBL] [Abstract][Full Text] [Related]
19. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
[TBL] [Abstract][Full Text] [Related]
20. A practical approach to hypercalcemia.
Carroll MF; Schade DS
Am Fam Physician; 2003 May; 67(9):1959-66. PubMed ID: 12751658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
